Copyright
©The Author(s) 2024.
World J Clin Cases. Jan 26, 2024; 12(3): 503-516
Published online Jan 26, 2024. doi: 10.12998/wjcc.v12.i3.503
Published online Jan 26, 2024. doi: 10.12998/wjcc.v12.i3.503
Table 1 Clinical characteristics of patients with suspected Angelman syndrome
Number of patients | Percentage (%) | |
Gender | 33 male; 17 female | |
Hypotonia | 100 | |
Neck support | (32/50) | 64 |
Walk without support | (21/50) | 42 |
Sitting without support | (38/50) | 76 |
Absent speech | (40/50) | 80 |
Developmental delay | 50/50) | 100 |
Severe mental retardation | (50/50) | 100 |
Microcephaly | (44/50) | 88 |
Macrostomia | (40/50) | 80 |
Clinical seizures | (44/50) | 88 |
Occipital groove | (45/50) | 90 |
Protruding tongue | (43/50) | 86 |
Wide-spaced teeth | (35/50) | 70 |
Prognathism | (40/50) | 80 |
Unusually light hair or skin color | (13/50) | 26 |
Easily provoked laughter | (50/50) | 100 |
Hyperactivity | (48/50) | 96 |
Gastro-esophageal reflux | (40/50) | 80 |
Ataxic movements | (48/50) | 96 |
Frequent drooling | (47/50) | 94 |
History of sleep difficulties | (45/50) | 90 |
Fascination with water | (40/50) | 80 |
Autistic behavior | (14/50) | 28 |
Table 2 Primer pairs used for single strand conformation polymorphism
Exon and primers | Forward and reverse primers (5’->3’) | Region | Annealing temperature (℃) |
7 | |||
Ex7F | GCC ACC TGA TCT GAC CAC T | Intron | 52 |
Ex7R | GCA GTC TAG GGC AAC TCA AA | Intron | |
8 | |||
Ex8AF | GCC TTG ATG ATA TGT TGA GC | Intron | 55 |
Ex8AR | AAT TCT AGC GCC TTT CTT GT | Exon | |
Ex8BF | GCC TGC ACG AAT GAG TTT TGT | Exon | 55 |
Ex8BR | AGT TAT TAT TCC TGT CCG TTA CC | Intron | |
9 | |||
Ex9AF | TGT TTG GCT GTT TTA CTT TTA GA | Intron | 55 |
Ex9AR | GGC ATC AAT ATC CAC AGA CAC A | Exon | |
Ex9BF | AGA AGC ATC TTC CTC AAG G | Exon | 55 |
Ex9BR | CAC TTC CCC TCC CAC TAC | Exon | |
Ex9CF | CAA TGA ATT TAA CAG TCG A | Exon | 55 |
Ex9CR | CAT CAT CTA TGA TAT GGT CAC G | Exon | |
Ex9DF | CGC ATG TAC AGT GAA CGA AGA A | Exon | 55 |
Ex9DR | TGC ACA GGA ACA ACA AAA GTA T | Intron | |
10 | |||
Ex10F | GTT TGC TTT CTG TTT CCA TTT AC | Intron | 52 |
Ex10R | ATC CTT CTT TTG CTG CTC TTC | Intron | |
11 | |||
Ex11F | CAA TGT TGC ATG CCT AAT TAC A | Intron | |
GGT ACT TCG GTC AGA TTA AAA C | Intron | ||
12 | |||
Ex12F | GGG GAC TGG AGG GAT ACT GT | Intron | 55 |
ACA TGC TTT GAA AGT GTT AAT G | Intron | ||
13 | |||
Ex13F | GAA ATT GTT AAG AAG TAG GTG | Intron | 52 |
Ex13R | ATA TGT CTT AGT TAT CTG CTA | Intron | |
14 | |||
Ex14F | AGG TGT CTG CAA AAA GTC | Intron | 55 |
Ex14R | TTA GCT CTG AAA AAT GGT G | Intron | |
15 | |||
Ex15F | ATA ATG AAT GCC AAA CTG AA | Intron | 55 |
Ex15R | ATA TGT ATG TGA CGA GGA ATG | Intron | |
16 | |||
Ex16F | CCC ATG ACT TAC AGT TTT CCT G | Intron | 55 |
Ex16R | AAG AAG GGA GGC ACA GAC AT | Intron |
Table 3 Ubiquitin-protein ligase E3A polymorphisms detected in our group of clinically diagnosed Angelman syndrome patients. The nucleotide and codon positions refer to the complete ubiquitin-protein ligase E3A cDNA sequence
Four common polymorphisms | New polymorphisms |
c.2064+9T>C → rs79328837 (intro13) | c.2220+14T>C (intron14) |
c.1713A>G → RS34670662 (exon 11) | c.30-47_30-46 insT (Exon7) |
c.2221-40_2221-38delGTA, RS149854051 (intron 14) | c.2507+43T>A (Exon15) |
c.486A>T; p.Ala162 =, RS28528079 (exon9A) |
Table 4 Identified exonic variants in the first consanguineous family
Gene (gene) | SHPRH | SLC30A9 | HBS1L | TAAR6 | TAAR2 | SASH1 | LOC100287896 | PCF11 | ANKRD42 | PDGFD | DIXDC1 |
Chromosome | 6 | 4 | 6 | 6 | 6 | 6 | 11 | 11 | 11 | 11 | 11 |
Location (varLocation) | Exonic | Intronic | intronic | Exonic | Exonic | Exonic | Exonic | Exotic | Exonic | Exonic | Exonic |
Effect (codingEffect) | Nonsynonymous | Nonsynonymous | Nonsynonymous | Nonsynonymous | Nonsynonymous | Nonsynonymous | Nonsynonymous | Nonsynonymous | Nonsynonymous | ||
cDNA (cNomen) | c.4331C>T | c.528-7T>C | c.2043+5T>G | c.865C>T | c.467C>T | c.1126C>T | c.4C>T | c.3355C>T | c.676A>G | c.7C>G | c.226G>A |
Protein (pNomen) | p.A1444V | p.P289S | p.T156I | p.P376S | p.R2C | p.H1119Y [Histidine (His)- Tyrosine (Tyr)] | p.N226D [Asparagine (Asn)- Aspartic Acid (Asp)] | p.R3G [Arginine (Arg)- Glycine (Gly)] | p.G76S [Glycine (Gly)- Serine (Ser)] | ||
Pathogenicity | 09/11 | This mutation probably has no impact on splicing | Activation of an intronic cryptic donor site. | 07/11 | 10/11 | 09/11 | 08/11 | 09/11 | 03/Nov | 0/11 | |
Potential alteration of splicing | |||||||||||
GME Variome (%) | Not available | Not available | Not available | 0.1 | Not available | Not available | Not available | 0.1 | 0.1 | 0.1 | Not available |
Gnomad browser (%) | 0.0008 | 0.04 | 0.2 | 0.006 | 0.001 | 0.001 | 0.4 | 0.2 | 0.3 | 0.01 | 0.002 |
Table 5 Identified exonic variants in the second consanguineous family
Gene (gene) | KMT5A | KMT5A | STK36 | PIK3CB | GPR149 | RARRES1 | KPNA4 | NOS1 | CAMKK2 | WDR66 | SBNO1 |
Chromosome | 12 | 12 | 2 | 3 | 3 | 3 | 3 | 12 | 12 | 12 | 12 |
Location (varLocation) | Exonic | Exonic | Exonic | Exonic | Exonic | Exonic | Exonic | Exonic | Exonic | Exonic | Intronic |
Effect (codingEffect) | Non-synonymous | Non-synonymous | Non-synonymous | Non-synonymous | Non-synonymous | Non-synonymous | Non-synonymous | Non-synonymous | Non-synonymous | Non-synonymous | Non-synonymous |
cDNA (cNomen) | c.904>C | c.995>C | c.2516 A | c.2150>G | c.1404A>C | c.230C>T | c.1103>G | c.1922>T | c.1612_1614dupAAA | c.196_197insAGAAAGAGGAGGAGG | c.3220+5C>G |
Protein (pNomen) | p.C302R | p.L332P | p.R839Q | p.N717S | p.R468S | p.P77L | p.N368S | p.A641V | p.K538dup | p.E65_G66insEKEEE | No significant splicing motif alteration detected. This mutation probably has no impact on splicing |
Pathogenicity | 03/11 | 10/11 | 06/11 | 01/11 | 01/11 | 10/11 | 03/11 | 09/11 | 01/11 | 01/11 | Not available |
GME Variome (%) | Not available | Not available | 0.05 | 0.9 | 0.1 | Not available | Not available | Not available | Not available | Not available | 0.01 |
Gnomad browser (%) | Not available | Not available | 0.7 | 0.1 | 0.04 | 0.004 | 0.003 | Not available | 12 | Not available | 0.01 |
Table 6 Gene expression in both Family 1 and Family 2
Gene | Function |
Gene expression in Family 1 | |
TAAR2 | Relevance to brain function and behavior, including schizophrenia, depression, anxiety, and drug addiction |
CITED2 | Gene is identified in human endothelial cells and neonatal brain. It is implicated in the development of the heart and neural tube |
HPRH | Ubiquitously expressed protein that contains motifs characteristics of several DNA repair proteins, transcription factors, and helicases. A possible candidate for the tumor suppressor gene |
SASH1 | Highly expressed in brain, heart, lung, ovary, and kidney. It is also identified as a candidate tumor suppressor gene in breast cancer |
DIXDC1 | Highly expressed in the brain and in specific brain regions; important in embryonic cortical development |
SLC30A9 | Shows ubiquitous expression in various human tissues, with high expression in the fetal brain, cerebellum, skeletal muscle, and kidney. Sub-cellular localization studies suggested that it is expressed in the vesicular cytosolic compartment, possibly in the endoplasmic reticulum |
Gene expression in Family 2 | |
KMT5A | Is a lysine methyl-transferase that predominantly mono-methylates lysine-20 (K20) of histone H4 |
SETD8 | Influences transcriptional regulation, heterochromatin formation, genomic stability, cell cycle progression, and development |
STK36 | Important for brain development |
PIK3CB | Plays a role in systemic insulin-like growth factor (IGF1) regulation and human longevity |
RARRES1 | Implicated in hyperproliferation, inflammatory skin diseases and, prostate cancer |
GPR149 | Increases fertility in mice, and causes prostatic cancer |
NOS1 | Important for the brain and peripheral nervous system |
SBNO1 | Implicated in cognition and psychoses, essential roles in vertebrate brain development |
- Citation: Manoubi W, Mahdouani M, Hmida D, Kdissa A, Rouissi A, Turki I, Gueddiche N, Soyah N, Saad A, Bouwkamp C, Elgersma Y, Mougou-Zerelli S, Gribaa M. Genetic investigation of the ubiquitin-protein ligase E3A gene as putative target in Angelman syndrome. World J Clin Cases 2024; 12(3): 503-516
- URL: https://www.wjgnet.com/2307-8960/full/v12/i3/503.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i3.503